2. Search Result
Search Result
Results for "

Advanced glycation end products

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

17

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-NP165
    Advanced glycation end products

    		Biochemical Assay Reagents Metabolic Disease
    Advanced glycation end products is a series of stable compounds produced by non-enzymatic reactions of reducing sugars with proteins, lipids or nucleic acids. Advanced glycation end products is often used as a target for evaluating the inhibitory effects of anti-glycosylation compounds .
    Advanced glycation end products
  • HY-14892A
    Gemigliptin tartrate

    LC15-0444 tartrate

    		 Dipeptidyl Peptidase Metabolic Disease
    Gemigliptin tartrate (LC15-0444 tartrate) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin tartrate exhibits potent anti-glycation properties. Gemigliptin tartrate can be used for the research of advanced glycation end products (AGE)-related diabetic complications .
    Gemigliptin tartrate
  • HY-N7628
    Cassiaside C

    Toralactone 9-O-β-D-gentiobioside

    		 Endogenous Metabolite Metabolic Disease
    Cassiaside C (Toralactone 9-O-β-D-gentiobioside) is a naphthopyrone isolated from the seed of Cassia tora and has inhibitory activity on advanced glycation end products (AGE) formation in vitro .
    Cassiaside C
  • HY-N0033
    Poliumoside
    5 Publications Verification

    		 Aldose Reductase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC50s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity .
    Poliumoside
  • HY-106024B
    Alagebrium chloride
    3 Publications Verification

    ALT711

    		 Endogenous Metabolite Metabolic Disease
    Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor.
    Alagebrium chloride
  • HY-B1745
    Pyridoxylamine
    3 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.
    Pyridoxylamine
  • HY-B1745A
    Pyridoxylamine dihydrochloride
    3 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .
    Pyridoxylamine dihydrochloride
  • HY-N0033R
    Poliumoside (Standard)

    		Reference Standards Aldose Reductase Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Poliumoside (Standard) is the analytical standard of Poliumoside. This product is intended for research and analytical applications. Poliumoside, a caffeoylated phenylpropanoid glycoside, is isolated from Brandisia hancei stems and leaves. Poliumoside is an advanced glycation end product (AGE) formation and rat lens aldose reductase (RLAR) inhibitor, with IC50s of 19.69 and 8.47 μM, respectively. Poliumoside also has antiinflammatory and antioxidant activity .
    Poliumoside (Standard)
  • HY-131528
    Tenilsetam

    CAS 997

    		 TNF Receptor Neurological Disease Metabolic Disease
    Tenilsetam (CAS 997) is an antidementia compound. Tenilsetam is an advanced glycation end product (AGE) inhibitor. Tenilsetam inhibits early retinopathy in experimental diabetes rats .
    Tenilsetam
  • HY-B1745R
    Pyridoxylamine (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    Pyridoxylamine (Standard) is the analytical standard of Pyridoxylamine. This product is intended for research and analytical applications. Pyridoxylamine is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions.
    Pyridoxylamine (Standard)
  • HY-B1745AR
    Pyridoxylamine dihydrochloride (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    Pyridoxylamine (dihydrochloride) (Standard) is the analytical standard of Pyridoxylamine (dihydrochloride). This product is intended for research and analytical applications. Pyridoxylamine dihydrochloride is an advanced glycation end production (AGEs) and lipoxidation end products (ALEs) inhibitor, to protect against diabetes-induced retinal vascular lesions .
    Pyridoxylamine dihydrochloride (Standard)
  • HY-Y0785
    Glyoxal

    		Drug Metabolite Neurological Disease Metabolic Disease
    Glyoxal is a cytotoxic α-oxoaldehyde. Glyoxal induces cell damage and promotes protein glycation to form advanced glycation end-products (AGEs). Glyoxal is promising for research of oxidative stress-related diseases (such as atherosclerosis, cataract, Alzheimer's disease), and the formation of calcium oxalate kidney stones .
    Glyoxal
  • HY-76383
    LR-90

    		COX Metabolic Disease Inflammation/Immunology
    LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes . LR-90 is also used in the research of diabetic animal model .
    LR-90
  • HY-N12071
    Lucidin-ω-Me ether

    		Others Others
    Lucidin-ω-Me ether (Compound 2) can be isolated from the roots of Knoxia valerianoides. Lucidin-ω-Me ether inhibits the advanced glycation end products (AGEs) formation in vitro(IC50: 62.79 μM) .
    Lucidin-ω-Me ether
  • HY-14892
    Gemigliptin

    LC15-0444

    		 Dipeptidyl Peptidase Metabolic Disease Cancer
    Gemigliptin (LC15-0444 ) is a highly selective, reversible and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, with an IC50 of 10.3 nM for human recombinant DPP-4. Gemigliptin exhibits potent anti-glycation properties. Gemigliptin can be used for the research of advanced glycation end products (AGE)-related diabetic complications .
    Gemigliptin
  • HY-N8375
    Sieboldin

    		Others Metabolic Disease
    Sieboldin is a dihydrochalcone, which inhibits the production of advanced glycation end products (AGE) produced by bovine serum albumins (BSA), has free radical scavenging activity and cytotoxicity in cancer cell lines, and is also used to capture of methylglyoxal (MGO) from Malus baccata .
    Sieboldin
  • HY-N7069
    4-Isopropylbenzyl alcohol

    		Others Cancer
    4-Isopropylbenzyl alcohol is a chemical composition of the essential oils from the leaves and flowers of Camellia nitidissima. C. nitidissima possess multiple biological activities including antioxidant activity, anticancer activity, and cytotoxicity as well as inhibiting the formation of advanced glycation end-products .
    4-Isopropylbenzyl alcohol
  • HY-168957
    RuDiOBn

    		MMP Reactive Oxygen Species (ROS) Others
    RuDiOBn scanvages DPPH and ABTS free radicals (13.2% and 5.9% clearance at 100 μg/mL), exhibits low antioxidant activity. RuDiOBn inhibits the collagen glycation, reduces the formation of advanced glycation end products (AGEs) with an IC50 of 2.45 μg/mL. RuDiOBn enhances the proliferation and migration of fibroblasts, stimulates the synthesis of collagen, promoting the skin repair and regeneration. RuDiOBn also inhibits collagenase .
    RuDiOBn
  • HY-50682A
    Azeliragon dihydrochloride

    TTP488 dihydrochloride; PF-04494700 dihydrochloride

    		 Amyloid-β Neurological Disease Cancer
    Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD) . Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB) .
    Azeliragon dihydrochloride
  • HY-50682
    Azeliragon
    Maximum Cited Publications
    12 Publications Verification

    TTP488; PF-04494700

    		 Amyloid-β Neurological Disease Cancer
    Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
    Azeliragon
  • HY-76383R
    LR-90 (Standard)

    		COX Metabolic Disease Inflammation/Immunology
    LR-90 (Standard) is the analytical standard of LR-90. This product is intended for research and analytical applications. LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes . LR-90 is also used in the research of diabetic animal model .
    LR-90 (Standard)
  • HY-114883
    Homocarnosine

    L-Homocarnosine; γ-Aminobutyryl-L-histidine

    		 GABA Receptor Endogenous Metabolite Neurological Disease Inflammation/Immunology
    Homocarnosine is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects .Homocarnosine has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
    Homocarnosine
  • HY-114883A
    Homocarnosine TFA
    1 Publications Verification

    L-Homocarnosine TFA; γ-Aminobutyryl-L-histidine TFA

    		 GABA Receptor Endogenous Metabolite Neurological Disease
    Homocarnosine TFA is a dipeptide of γ-aminobutyric acid (GABA) and histidine unique to brain. Homocarnosine TFA is an inhibitory neuromodulator synthesized in the neuron from GABA and exhibiting anticonvulsant effects . Homocarnosine TFA has antioxidant and anti-inflammatory actions, prevention of DNA damage, and inhibition of advanced glycation end-product formation .
    Homocarnosine TFA
  • HY-50682R
    Azeliragon (Standard)

    		Amyloid-β Neurological Disease Cancer
    Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
    Azeliragon (Standard)
  • HY-P2268
    RAGE antagonist peptide
    3 Publications Verification

    		 Amyloid-β Inflammation/Immunology Cancer
    RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities .
    RAGE antagonist peptide
  • HY-B1235
    Acetohydroxamic acid
    1 Publications Verification

    N-Hydroxyacetamide

    		 Bacterial HIV Infection Inflammation/Immunology
    Acetohydroxamic acid is the inhibitor for bacterial and plant urease that can be used for chronic urinary tract infections. Acetohydroxamic acid selectively inhibits arachidonic acid 5-lipoxygenase that is useful in the research of asthma. Acetohydroxamic acid inhibits the formation of advanced glycation end products, and reduces oxidative stress and inflammatory responses. Acetohydroxamic acid exhibits antiviral activity against HIV .
    Acetohydroxamic acid
  • HY-113033
    Pentosidine

    		Others Neurological Disease Metabolic Disease
    Pentosidine is an advanced glycation end product (AGE) and cross-linked substance with fluorescent properties. Pentosidine is present in various human tissues and can serve as a biomarker for diabetes, aging, uremia, protein accumulation damage, and non-enzymatic modification of long-lived proteins in the Maillard reaction. It aids in gaining a deeper understanding of the overall role of the Maillard reaction in aging and disease .
    Pentosidine
  • HY-P2268A
    RAGE antagonist peptide TFA
    3 Publications Verification

    		 Amyloid-β Inflammation/Immunology Cancer
    RAGE antagonist peptide TFA is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide TFA prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide TFA possesses anti-tumor and anti-inflammatory activities .
    RAGE antagonist peptide TFA
  • HY-113033A
    Pentosidine TFA

    		Biochemical Assay Reagents Neurological Disease Metabolic Disease
    Pentosidine TFA is an advanced glycation end product (AGE) and cross-linked substance with fluorescent properties. Pentosidine TFA is present in various human tissues and can serve as a biomarker for diabetes, aging, uremia, protein accumulation damage, and non-enzymatic modification of long-lived proteins in the Maillard reaction. It aids in gaining a deeper understanding of the overall role of the Maillard reaction in aging and disease .
    Pentosidine TFA
  • HY-N4170
    Chebulic acid
    1 Publications Verification

    		 Keap1-Nrf2 Reactive Oxygen Species (ROS) Metabolic Disease
    Chebulic acid is a phenolic acid compound isolated from Terminalia chebula with strong antioxidant activity, which breaks protein cross-links induced by advanced glycation end products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress, and liver damage, supporting its beneficial role in asthma, diabetes, and liver protection .
    Chebulic acid
  • HY-B1235R
    Acetohydroxamic acid (Standard)

    N-Hydroxyacetamide (Standard)

    		 Reference Standards Bacterial HIV Infection Inflammation/Immunology
    Acetohydroxamic acid (Standard) is the analytical standard of Acetohydroxamic acid. This product is intended for research and analytical applications. Acetohydroxamic acid is the inhibitor for bacterial and plant urease that can be used for chronic urinary tract infections. Acetohydroxamic acid selectively inhibits arachidonic acid 5-lipoxygenase that is useful in the research of asthma. Acetohydroxamic acid inhibits the formation of advanced glycation end products, and reduces oxidative stress and inflammatory responses. Acetohydroxamic acid exhibits antiviral activity against HIV .
    Acetohydroxamic acid (Standard)
  • HY-N7426
    3-Deoxyglucosone

    3-Deoxy-D-glucosone

    		 GLP Receptor Metabolic Disease
    3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes .
    3-Deoxyglucosone
  • HY-129611
    Bromelain

    		Apoptosis Inflammation/Immunology Cancer
    Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .
    Bromelain
  • HY-147329
    RAGE 229

    		Transmembrane Glycoprotein Metabolic Disease
    RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1) .
    RAGE 229
  • HY-B1392A
    Esmolol

    		Adrenergic Receptor Caspase Apoptosis Aldose Reductase Neurokinin Receptor Cardiovascular Disease Endocrinology Cancer
    Esmolol is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol attenuates post resuscitation myocardial dysfunction. Esmolol improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .
    Esmolol
  • HY-B1392
    Esmolol hydrochloride
    3 Publications Verification

    		 Adrenergic Receptor Caspase Apoptosis Aldose Reductase Neurokinin Receptor Cardiovascular Disease Endocrinology Cancer
    Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol hydrochloride attenuates post resuscitation myocardial dysfunction. Esmolol hydrochloride improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .
    Esmolol hydrochloride
  • HY-146619
    RAGE/SERT-IN-1

    		Amyloid-β Serotonin Transporter Neurological Disease
    RAGE/SERT-IN-1 is a potent and orally active advanced glycation end products (RAGE) and serotonin transporter (SERT) inhibitor with IC50s of 8.26 μM and 31.09 nM, respectively. RAGE/SERT-IN-1 exhibits significant neuroprotective effect against Aβ25-35-induced neuronal damage and alleviates depressive behavior of mice. RAGE/SERT-IN-1 can be used for researching the comorbidity of Alzheimer's disease and depression .
    RAGE/SERT-IN-1
  • HY-B1392R
    Esmolol hydrochloride (Standard)

    		Reference Standards Adrenergic Receptor Autophagy Mitophagy Cardiovascular Disease Endocrinology Cancer
    Esmolol hydrochloride (Standard) is the analytical standard of Esmolol hydrochloride (HY-B1392).This product is intended for research and analytical applications. Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptoraldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .
    Esmolol hydrochloride (Standard)
  • HY-B1392S
    Esmolol-d7 hydrochloride

    		Isotope-Labeled Compounds Adrenergic Receptor Autophagy Mitophagy Cardiovascular Disease Endocrinology Cancer
    Esmolol-d7 hydrochloride is the deuterium labeled Esmolol hydrochloride (HY-B1392). Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptoraldose reductase) and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .
    Esmolol-d7 hydrochloride
  • HY-W585874
    Nε-(Carboxyethyl)lysine

    		EAAT Neurological Disease
    Nε-(Carboxyethyl)lysine is an advanced glycation end product (AGE). Nε-(Carboxyethyl)lysine causes cross-linking between proteins, affects the structure and function of proteins, and leads to protein denaturation. Nε-(Carboxyethyl)lysine binds to RAGE receptors, affects cell signaling, regulates processes such as inflammatory response, cell proliferation and apoptosis. Nε-(Carboxyethyl)lysine affects glutamate transporter, reduces glutamate uptake and S100B protein secretion, affects neurotransmission in the nervous system, and exhibits diabetic-related neurotoxicity .
    Nε-(Carboxyethyl)lysine
  • HY-124750
    NecroX-7

    		TNF Receptor Interleukin Related Toll-like Receptor (TLR) Reactive Oxygen Species (ROS) Cardiovascular Disease Inflammation/Immunology
    NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research .
    NecroX-7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: